Compare Abbott Laboratories (ABT) vs Hut 8 Corp (HUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Hut 8 Corp — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Hut 8 Corp trades at $97.9 (market cap $10.89B). The key difference: Abbott Laboratories is far larger — about 15.3× Hut 8 Corp's market cap, and Abbott Laboratories pays a 2.63% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| ABT | HUT | |
|---|---|---|
Market Cap | $166.94B | $10.89B |
Sector | Health | Technology |
52-Week High | $136.62 | $133.02 |
52-Week Low | $82.57 | $19.45 |
Enterprise Value | $193.69B | $11.15B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
HUT trades at $103.78, up 6.84% today, but faces bearish technical signals with resistance at $108. The company shows strong analyst support (93.75% buy ratings) with a $129.44 consensus target, yet fundamentals reveal challenges: negative net income margin of -109.77% in 2025 and operating cash flow of -$139.23M. Recent news highlights Hut 8's pivot to AI infrastructure, closing $4.25B in project financing for data centers, signaling strategic growth amid profitability concerns.
Outlook: High growth potential from AI/data center expansion, but elevated execution risks and persistent losses warrant caution. Near-term price movement may hinge on Q2 2026 earnings (expected EPS -$0.32) and Bitcoin market volatility. Risks include competitive pressures and reliance on financing for cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
